| Atrial Fibrillation
Pradaxa vs Eliquis
Side-by-side clinical, coverage, and cost comparison for atrial fibrillation.Deep comparison between: Pradaxa vs Eliquis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEliquis has a higher rate of injection site reactions vs Pradaxa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Eliquis but not Pradaxa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Pradaxa
Eliquis
At A Glance
Oral
Twice daily
Direct thrombin inhibitor
Oral
Twice daily
Factor Xa inhibitor
Indications
- Atrial Fibrillation
- Deep Vein Thrombosis
- Pulmonary Embolism
- Atrial Fibrillation
- Deep Vein Thrombosis
- Pulmonary Embolism
- Venous Thromboembolism
Dosing
Atrial Fibrillation CrCl > 30 mL/min: 150 mg orally twice daily; CrCl 15-30 mL/min: 75 mg orally twice daily; reduce to 75 mg twice daily if CrCl 30-50 mL/min with concomitant dronedarone or systemic ketoconazole.
Deep Vein Thrombosis, Pulmonary Embolism Treatment: 150 mg orally twice daily after 5-10 days of parenteral anticoagulation (CrCl > 30 mL/min); recurrence reduction: 150 mg orally twice daily after previous treatment (CrCl > 30 mL/min).
Prophylaxis of DVT and PE Following Hip Replacement Surgery 110 mg orally on day 1 (1-4 hours after surgery and after hemostasis), then 220 mg once daily for 28-35 days (CrCl > 30 mL/min).
Pediatric VTE Weight-based dosage orally twice daily after at least 5 days of parenteral anticoagulant (ages 8 to <18 years); adjust dose per actual weight as treatment progresses.
Atrial Fibrillation 5 mg orally twice daily; 2.5 mg twice daily in patients with at least 2 of the following: age >=80 years, body weight <=60 kg, or serum creatinine >=1.5 mg/dL.
Deep Vein Thrombosis (prophylaxis, hip or knee replacement) 2.5 mg orally twice daily initiated 12-24 hours post-surgery; 35 days for hip replacement, 12 days for knee replacement.
Deep Vein Thrombosis, Pulmonary Embolism (treatment) 10 mg orally twice daily for 7 days, then 5 mg twice daily.
Deep Vein Thrombosis, Pulmonary Embolism (recurrence reduction) 2.5 mg orally twice daily after at least 6 months of treatment for DVT or PE.
Venous Thromboembolism (pediatric) Weight-based dosing orally twice daily following at least 5 days of initial anticoagulant treatment; doses range from 0.3 mg to 10 mg twice daily based on weight tier.
Contraindications
- Active pathological bleeding
- History of serious hypersensitivity reaction to dabigatran, dabigatran etexilate, or any excipient (e.g., anaphylactic reaction or anaphylactic shock)
- Mechanical prosthetic heart valve
- Active pathological bleeding
- Severe hypersensitivity reaction to apixaban (e.g., anaphylactic reactions)
Adverse Reactions
Most common Bleeding events (major and minor), gastrointestinal adverse reactions (dyspepsia, nausea, vomiting, upper abdominal pain, diarrhea, gastritis-like symptoms)
Serious Intracranial hemorrhage, major gastrointestinal hemorrhage, anaphylactic reaction, anaphylactic shock
Postmarketing Agranulocytosis, neutropenia, thrombocytopenia, esophageal ulcer, angioedema, anticoagulant-related nephropathy, alopecia
Most common (>=1%) Epistaxis, contusion, hematuria, menorrhagia, hematoma, hemoptysis, rectal hemorrhage, gingival bleeding, nausea, anemia.
Serious Major bleeding including intracranial hemorrhage, gastrointestinal bleeding, and fatal bleeding.
Pharmacology
Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors that prevent thrombus formation by blocking thrombin-mediated conversion of fibrinogen to fibrin and inhibiting thrombin-induced platelet aggregation, acting on both free and clot-bound thrombin.
Apixaban is a selective inhibitor of factor Xa (FXa) that does not require antithrombin III for antithrombotic activity; by inhibiting free and clot-bound FXa and prothrombinase activity, it decreases thrombin generation and thrombus development without directly affecting platelet aggregation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Pradaxa
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Eliquis
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Pradaxa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (1/8)
Eliquis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Pradaxa
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Eliquis
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Pradaxa.
No savings programs available for Eliquis.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PradaxaView full Pradaxa profile
EliquisView full Eliquis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.